title: Metabolic syndrome associated with hyperprolactinemia: a new indication for dopamine agonist treatment?
authors: Endocrinology Division, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, Spain.
authors: Ignacio
authors: I
authors: Bernabeu
authors: Felipe F
authors: FF
authors: Casanueva
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D015415:Biomarkers / Q000097:blood*; D059168:Carotid Intima-Media Thickness; D004873:Ergolines / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood*; D007333:Insulin Resistance; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D015175:Prolactinoma / Q000188:drug therapy*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D015415:Biomarkers; D004873:Ergolines
references: Clin J Am Soc Nephrol. 2012 Feb;7(2):207-15
references: 22193237
references: Diabetes Obes Metab. 2007 Jul;9(4):464-76
references: 17587388
references: Endocr Rev. 2008 Feb;29(1):1-41
references: 18057139
references: Eur Heart J. 2014 May;35(18):1215-21
references: 22843444
references: Clin Endocrinol (Oxf). 2007 Dec;67(6):845-52
references: 17645576
references: Pituitary. 2011 Sep;14(3):199-207
references: 21128120
references: Endocr Rev. 2000 Jun;21(3):292-312
references: 10857555
references: Clin Endocrinol (Oxf). 2006 Apr;64(4):366-70
references: 16584506
references: Clin Endocrinol (Oxf). 2006 Aug;65(2):265-73
references: 16886971
references: Obesity (Silver Spring). 2011 Apr;19(4):800-5
references: 20559294
references: Obes Res. 2003 Feb;11(2):311-2
references: 12582229
references: Endocrine. 2013 Aug;44(1):193-9
references: 23233277
references: Trends Endocrinol Metab. 2006 Apr;17(3):110-6
references: 16517173